These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22665363)

  • 1. Fuel, electricity, ER and HER2--a hybrid-car model of breast cancer.
    Saji S; Sato F; Ueno NT
    Nat Rev Clin Oncol; 2012 Jun; 9(7):. PubMed ID: 22665363
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormone receptor status might be a determinant for HER2 loss after HER2-targeted treatment in HER2 positive breast cancer patients.
    Altundag K
    J BUON; 2019; 24(5):2206. PubMed ID: 31786897
    [No Abstract]   [Full Text] [Related]  

  • 3. The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
    Stravodimou A; Voutsadakis IA
    Anticancer Res; 2020 Sep; 40(9):4829-4841. PubMed ID: 32878771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 and hormone receptor-positive breast cancer--blocking the right target.
    Cortés J; Saura C; Bellet M; Muñoz-Couselo E; Ramírez-Merino N; Calvo V; Pérez J; Vidal M
    Nat Rev Clin Oncol; 2011 May; 8(5):307-11. PubMed ID: 21151204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous targeting of estrogen receptor and HER2 in breast cancer.
    Azim HA; Piccart MJ
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1255-63. PubMed ID: 20735311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does lapatinib work against HER2-negative breast cancers?
    Mayer IA; Arteaga CL
    Clin Cancer Res; 2010 Mar; 16(5):1355-7. PubMed ID: 20179241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
    Roukos DH
    J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
    [No Abstract]   [Full Text] [Related]  

  • 10. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
    Wu VS; Kanaya N; Lo C; Mortimer J; Chen S
    J Steroid Biochem Mol Biol; 2015 Sep; 153():45-53. PubMed ID: 25998416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):4. PubMed ID: 19364050
    [No Abstract]   [Full Text] [Related]  

  • 12. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?
    Groheux D; Hindié E
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1571-3. PubMed ID: 27245758
    [No Abstract]   [Full Text] [Related]  

  • 14. Triple-negative breast cancer.
    Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance to Anti-HER2 Therapies in Breast Cancer.
    Rimawi MF; De Angelis C; Schiff R
    Am Soc Clin Oncol Educ Book; 2015; ():e157-64. PubMed ID: 25993167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of small node-negative ER+/HER2+ and ER-/HER2+breast cancers might be different.
    Altundag K
    J BUON; 2020; 25(1):583. PubMed ID: 32277688
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Burstein HJ
    N Engl J Med; 2020 Dec; 383(26):2557-2570. PubMed ID: 33369357
    [No Abstract]   [Full Text] [Related]  

  • 19. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
    van de Ven S; Smit VT; Dekker TJ; Nortier JW; Kroep JR
    Cancer Treat Rev; 2011 Oct; 37(6):422-30. PubMed ID: 21177040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
    Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R
    Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.